Generic Drug Report 2012

Generic Drug Report 2012

BY DSN STAFF

The year 2012 is coming to an end, and it’s been a big year for generic drugs. It’s the year that the most lucrative drug of all time became commoditized. It’s the year that Watson bought Actavis for $5.6 billion. And it’s the year the FDA released draft guidance for biosimilars regulations. All of these events speak to some of the most important trends in the world of generics — trends that are often interrelated.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?